Cognitive Behavioral Therapy and Real-Time Pain Management Intervention for Sickle Cell Via Mobile Applications (CaRISMA)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04419168 |
Recruitment Status :
Active, not recruiting
First Posted : June 5, 2020
Last Update Posted : January 9, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Chronic Pain Depression, Anxiety Opioid Use | Other: cCBT Other: m-Education | Not Applicable |
The study interventions are both Internet-delivered, evidence-based tools that have been tailored specifically for the target population through a user-centered approach that has engaged stakeholders at each stage of the process.
- Computerized cognitive behavioral therapy (cCBT) for pain. The cCBT program will teach users how to recognize negative thoughts and emotions, use cognitive skills and problem-solving, and apply coping behaviors such as distraction, activity scheduling, and relaxation. The cCBT arm emphasizes skills acquisition and learning through practice; this intervention is consistent with the tailored behavioral services patients would receive individually or as a group when working with a psychologist or behavioral pain specialist.
- Mobile-delivered pain and sickle cell disease education (m-Education). The m-Education program will teach users about chronic pain, healthy lifestyle tips (e.g., nutrition and exercise), and facts about SCD. This program is consistent with the education patients and families would receive with a patient educator.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 350 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Intervention Model Description: | comparative effectiveness trial |
Masking: | Single (Participant) |
Primary Purpose: | Treatment |
Official Title: | Cognitive Behavioral Therapy and Real-Time Pain Management Intervention for Sickle Cell Via Mobile Applications |
Actual Study Start Date : | August 12, 2020 |
Estimated Primary Completion Date : | November 2023 |
Estimated Study Completion Date : | November 2023 |

Arm | Intervention/treatment |
---|---|
Experimental: cCBT
Computerized cognitive behavioral therapy (cCBT) for pain. The cCBT program will teach users how to recognize negative thoughts and emotions, use cognitive skills and problem-solving, and apply coping behaviors such as distraction, activity scheduling, and relaxation. The cCBT arm emphasizes skills acquisition and learning through practice; this intervention is consistent with the tailored behavioral services patients would receive individually or as a group when working with a psychologist or behavioral pain specialist.
|
Other: cCBT
A digital, internet-delivered, evidence-based chatbot programmed to deliver content for both cCBT. |
Experimental: m-Education
Mobile-delivered pain and sickle cell disease education (m-Education). The m-Education program will teach users about chronic pain, healthy lifestyle tips (e.g., nutrition and exercise), and facts about SCD. This program is consistent with the education patients and families would receive with a patient educator.
|
Other: m-Education
A digital, internet-delivered, evidence-based chatbot programmed to deliver content for both m-Education. |
No Intervention: Convenience Comparison
Not participating in the intervention. Participants will complete the baseline questionnaire battery only and we will abstract their medical record data for the 12-months before enrollment and 12-months post enrollment.
|
- Change in Pain interference [ Time Frame: 3, 6, 12 months ]- PROMIS (Patient-Reported Outcomes Measurement Information System) Pain Interference Scale a validated questionnaire that assesses how day-to-day function is altered by pain. Range 8-40, higher scores may mean that pain limits your activity level and enjoyment of certain activities
- Change in Daily pain intensity [ Time Frame: 3, 6, 12 months ]Daily pain intensity: 3, 6 and 12-month change in average daily pain intensity "Using any number from 0 to 10, where 0 is no pain and 10 is the worst pain imaginable, what is your pain level today?"

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- People with any type of sickle cell disease
- Male or female, age 18 years or older
- Reports chronic pain: i.e pain more days that not for the past 3 months or longer and/or is prescribed daily or long-acting opioids for pain.
- English speaking
Exclusion Criteria:
- Any potential participants who fail consent comprehension questions

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04419168
United States, Illinois | |
University of Illinous-Chicago | |
Chicago, Illinois, United States, 60607 | |
United States, Maryland | |
Johns Hopkins | |
Baltimore, Maryland, United States, 21287 | |
United States, North Carolina | |
Duke University | |
Durham, North Carolina, United States, 27708 | |
East Carolina University | |
Greenville, North Carolina, United States, 27858 | |
United States, Ohio | |
Ohio State University | |
Columbus, Ohio, United States, 43210 | |
United States, Pennsylvania | |
University of Pittsburgh | |
Pittsburgh, Pennsylvania, United States, 15213 | |
United States, Tennessee | |
Vanderbilt University | |
Nashville, Tennessee, United States, 37240 |
Responsible Party: | Kaleab Abebe, PhD, Associate Professor, University of Pittsburgh |
ClinicalTrials.gov Identifier: | NCT04419168 |
Other Study ID Numbers: |
STUDY20110346 CER-2018C2-13320 20 ( Other Grant/Funding Number: PCORI ) |
First Posted: | June 5, 2020 Key Record Dates |
Last Update Posted: | January 9, 2023 |
Last Verified: | January 2023 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
sickle cell disease pain opioids depression cognitive behavioral therapy |
mobile technology digital health mHealth implementation science community-based participatory research |
Chronic Pain Depression Behavioral Symptoms Pain Neurologic Manifestations |